Patents by Inventor Marco PEVIANI

Marco PEVIANI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250236600
    Abstract: The present invention is comprised in the field of medicinal chemistry, and it is related to substituted vinyl piperazine-piperidine urea compound which are well effective as antitumoral agents. In particular, they are suitable in methods of treatment of glioblastoma (GB), multiple myeloma (MM) or pancreatic cancer (PC).
    Type: Application
    Filed: June 20, 2022
    Publication date: July 24, 2025
    Inventors: Simona COLLINA, Daniela ROSSI, Pasquale LINCIANO, Giacomo ROSSINO, Roberta LISTRO, Marco PEVIANI, Silvia Stefania ROSSI, Barbara VIGANI, Guido Angelo CAVALETTI, Mariarosaria MILOSO, Alessio MALACRIDA
  • Publication number: 20250049839
    Abstract: The present invention provides compositions and methods for targeting cells for therapeutic and/or diagnostic purposes, e.g., delivery of therapeutic and/or diagnostic agents to a cell. Nanoparticles and polymers functionalized with capture molecules, reporter molecules, and/or therapeutic agents are provided for the treatment or prevention of disease, including neurological diseases associated with neuroinflammation, and cancer.
    Type: Application
    Filed: October 31, 2024
    Publication date: February 13, 2025
    Applicants: Children's Medical Center Corporation, Politecnico di Milano, Dana-Farber Cancer Institute, Inc.
    Inventors: Marco Peviani, Alessandra Biffi, Davide Moscatelli, Umberto Capasso Palmiero, Renato Auriemma, Mattia Sponchioni, Letterio Salvatore Politi
  • Patent number: 12161663
    Abstract: The present invention provides compositions and methods for targeting cells for therapeutic and/or diagnostic purposes, e.g., delivery of therapeutic and/or diagnostic agents to a cell. Nanoparticles and polymers functionalized with capture molecules, reporter molecules, and/or therapeutic agents are provided for the treatment or prevention of disease, including neurological diseases associated with neuroinflammation, and cancer.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: December 10, 2024
    Assignees: Children's Medical Center Corporation, Politecnico di Milano, Dana-Farber Cancer Institute, Inc.
    Inventors: Marco Peviani, Alessandra Biffi, Davide Moscatelli, Umberto Capasso Palmiero, Renato Auriemma, Mattia Sponchioni, Letterio Salvatore Politi
  • Publication number: 20240269169
    Abstract: The present invention provides compositions and methods for the treatment or prevention of a neurological disease or disorder of the central nervous system (e.g., a storage disorder, lysosomal storage disorder, neurodegenerative disease, etc.) by reconstitution of brain myeloid cell and microglia upon transplantation of hematopoietic cells enriched in microglia reconstitution potential. The invention also provides compositions and methods for ablating and reconstituting microglia.
    Type: Application
    Filed: December 29, 2023
    Publication date: August 15, 2024
    Applicants: The Children's Medical Center Corporation, Ospedale San Raffaele S.r.l., Politecnico di Milano, Fondazione Telethon ETS, Dana-Farber Cancer Institute, Inc.
    Inventors: Alessandra BIFFI, Marco PEVIANI, Davide MOSCATELLI, Alessia CAPOTONDO, Rita MILAZZO, Umberto CAPASSO PALMIERO
  • Patent number: 11957713
    Abstract: The present invention provides compositions and methods for the treatment or prevention of a neurological disease or disorder of the central nervous system (e.g., a storage disorder, lysosomal storage disorder, neurodegenerative disease, etc.) by reconstitution of brain myeloid cell and microglia upon transplantation of hematopoietic cells enriched in microglia reconstitution potential. The invention also provides compositions and methods for ablating and reconstituting microglia.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: April 16, 2024
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, OSPEDALE SAN RAFFAELE S.R.L., POLITECNICO DI MILANO, FONDAZIONE TELETHON ETS, DANA-FARBER CANCER INSTITUTE, INC
    Inventors: Alessandra Biffi, Marco Peviani, Davide Moscatelli, Alessia Capotondo, Rita Milazzo, Umberto Capasso Palmiero
  • Publication number: 20220378942
    Abstract: The present disclosure features methods and compositions for treating Alzheimer's disease. The disclosed methods comprise administering to a subject having or suspected of having Alzheimer's a hematopoietic stem progenitor cell expressing at least one neuroprotective agent, such as ApoE2, Trem2, and/or a metallothionein.
    Type: Application
    Filed: October 1, 2020
    Publication date: December 1, 2022
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Alessandra BIFFI, Marco PEVIANI
  • Publication number: 20220348962
    Abstract: The present disclosure features methods and compositions for expressing transgenes in microglia. The disclosed compositions comprise isolated fragments of human and murine translocator protein (TSPO) promoters and expression cassettes comprising the same. The methods involve using these promoters and/or expression cassettes to express transgenes in a cell.
    Type: Application
    Filed: October 1, 2020
    Publication date: November 3, 2022
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Alessandra BIFFI, Valentina POLETTI, Marco PEVIANI, Francisco J. MOLINA-ESTEVEZ
  • Publication number: 20220290157
    Abstract: The present disclosure features methods and compositions for treating amyotrophic lateral sclerosis (ALS). The disclosed methods comprise administering to a subject having or suspected of having ALS a hematopoietic stem progenitor cell expressing at least one neuroprotective agent. The compositions disclosed comprise hematopoietic stem progenitor cells transduced to express a neuroprotective agent.
    Type: Application
    Filed: March 31, 2022
    Publication date: September 15, 2022
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Alessandra BIFFI, Marco PEVIANI, Francisco J. MOLINA-ESTEVEZ
  • Publication number: 20210046105
    Abstract: The present invention provides compositions and methods for targeting cells for therapeutic and/or diagnostic purposes, e.g., delivery of therapeutic and/or diagnostic agents to a cell. Nanoparticles and polymers functionalized with capture molecules, reporter molecules, and/or therapeutic agents are provided for the treatment or prevention of disease, including neurological diseases associated with neuroinflammation, and cancer.
    Type: Application
    Filed: September 28, 2020
    Publication date: February 18, 2021
    Applicants: Children's Medical Center Corporation, Politecnico di Milano, Dana-Farber Cancer Institute, Inc.
    Inventors: Marco Peviani, Alessandra Biffi, Davide Moscatelli, Umberto Capasso Palmiero, Renato Auriemma, Mattia Sponchioni, Letterio Salvatore Politi
  • Publication number: 20200038439
    Abstract: The present invention provides compositions and methods for the treatment or prevention of a neurological disease or disorder of the central nervous system (e.g., a storage disorder, lysosomal storage disorder, neurodegenerative disease, etc.) by reconstitution of brain myeloid cell and microglia upon transplantation of hematopoietic cells enriched in microglia reconstitution potential. The invention also provides compositions and methods for ablating and reconstituting microglia.
    Type: Application
    Filed: October 16, 2017
    Publication date: February 6, 2020
    Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, OSPEDALE SAN RAFFAELE S.R.L., POLITECNICO DI MILANO, FONDAZIONE TELETHON
    Inventors: ALESSANDRA BIFFI, MARCO PEVIANI, DAVIDE MOSCATELLI, ALESSIA CAPATANDO, RITA MILAZZO, UMBERTO CAPASSO PALMIERO
  • Publication number: 20170015640
    Abstract: The present invention relates to the use of arylalkanolamine compounds with sigma-1 receptor antagonist activity. In particular, the said arylalkanolamine compounds are useful in the treatment of conditions selected from the abuse of psychotropic substances such as cocaine or amphetamines, pain and cancer.
    Type: Application
    Filed: March 4, 2015
    Publication date: January 19, 2017
    Inventors: Simona COLLINA, Daniela ROSSI, Annamaria MARRA, Marco PEVIANI, Daniela CURTI